Rifaximin
| Evidence Level: L4 | Predicted Indications: 6 |
Table of Contents
- Rifaximin
- Rifaximin: Original Indication Unavailable — Predicted New Indication “Oral Candidiasis” Not Supported by Mechanistic or Clinical Evidence
Rifaximin: Original Indication Unavailable — Predicted New Indication “Oral Candidiasis” Not Supported by Mechanistic or Clinical Evidence
One-Sentence Summary
Rifaximin is a gut-acting, non-absorbable antibacterial agent; this evidence pack contains no registered original indication for India, and the drug is currently not marketed there. TxGNN’s top prediction is oral candidiasis (score 99.75%), but the only literature identified reports the opposite signal — rifaximin use was associated with an increase in micafungin-resistant Candida infections, not therapeutic benefit. With no clinical trials, a single risk-signal publication, and a mechanistic mismatch (antibacterial vs. antifungal), the evidence level is L4 and the recommendation is Hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no registry/license data in this evidence pack |
| Predicted New Indication | Oral candidiasis |
| TxGNN Prediction Score | 99.75% |
| Evidence Level | L4 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Based on the evidence pack, this prediction is not mechanistically well-supported. Rifaximin is a non-absorbable, gut-restricted antibacterial agent (an RNA polymerase inhibitor) with no known antifungal activity. Oral candidiasis is a fungal infection, so there is no established pharmacological pathway linking rifaximin’s antibacterial mechanism to antifungal efficacy.
The single literature reference associated with this candidate (PMID 34180023) does not provide therapeutic support — it reports the reverse: rifaximin use was associated with an increased incidence of micafungin-resistant Candida infections in allogeneic hematopoietic stem cell transplant recipients, likely due to gut microbiota disruption favoring fungal overgrowth. This is a risk signal, not evidence of efficacy.
Detailed mechanism-of-action data for rifaximin was not available in this pack (flagged as a High-severity data gap), which further limits confidence in any mechanistic rationale. Given the clear disconnect between rifaximin’s known antibacterial action and the fungal disease target, plus the absence of any supportive clinical or preclinical data, this candidate does not currently meet the bar for further exploration.
Note: All other predicted indications in this pack (ranks 2–6, e.g., commissural lip fistula, osteoradionecrosis of the mandible, burning mouth syndrome, oral leukoedema, candidiasis) also received Hold recommendations, most at evidence level L5 with no literature or trial support at all — indicating these are model-score-only predictions without independent corroboration.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34180023 | 2021 | Cohort/Case series | Annals of Hematology | In allogeneic HSCT recipients, rifaximin use was associated with an increase in micafungin-resistant Candida spp. infections — a safety/risk signal, not evidence of antifungal efficacy |
India Market Information
Rifaximin is currently not marketed in India, and no registration/license records are present in this evidence pack.
Safety Considerations
- Drug Interactions: 69 total interactions identified via DDInter. Notable entries include:
- Major: Vibrio cholerae CVD 103-HgR live vaccine — co-administration with rifaximin (an antibacterial) may reduce vaccine effectiveness
- Moderate: Warfarin, Cyclosporine, Daclatasvir, Ledipasvir, Tolvaptan, Encorafenib, Cabozantinib, Enasidenib, Elagolix, Elexacaftor, Eliglustat, Darolutamide, Capmatinib, Brigatinib, Bempedoic acid, Apalutamide, Alpelisib, Istradefylline, Picosulfuric acid
Detailed key warnings and contraindications (e.g., from local package insert) were not available in this evidence pack — this is flagged as a Blocking data gap that prevents completion of a full initial safety assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (oral candidiasis) lacks any mechanistic or clinical rationale — the only supporting literature actually documents a risk of increased fungal infection with rifaximin use, not efficacy. Combined with zero clinical trials, no marketing authorization in India, and missing core safety label data, this candidate does not warrant progression at this time.
To proceed, the following is needed:
- TFDA/India package insert warnings and contraindications (currently Blocking data gap — required before any S1 safety screening)
- Confirmed mechanism-of-action data for rifaximin (High-severity data gap)
- Independent efficacy evidence (in vitro, preclinical, or clinical) directly supporting an antifungal or anti-candidiasis effect, given the existing literature points in the opposite direction
- Reassessment of whether any of the other five predicted indications (all L5, unsupported) warrant separate evidence-gathering before further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.